<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"><channel><title><![CDATA[Quiver Bioscience 보도자료 - 뉴스와이어]]></title><link>https://www.newswire.co.kr/?md=A10&amp;act=article&amp;no=50190></link><description><![CDATA[Quiver Bioscience 보도자료 - 뉴스와이어 RSS 서비스]]></description><lastBuildDate>Tue, 14 Apr 2026 04:46:15 +0900</lastBuildDate><copyright>Copyright (c) 2004~2026 Korea Newswire All rights reserved</copyright><image><url><![CDATA[https://file.newswire.co.kr/data/upfile/company_img/2026/02/12_31017998_20260224162426_6400793462.jpg]]></url></image><language>ko-KR</language><item><title><![CDATA[Angelini Pharma and Quiver Bioscience Announce Strategic Research Collaboration and Licensing Agreement to Discover and Advance Novel Therapeutics for Genetic Epilepsies]]></title><link>https://www.newswire.co.kr/newsRead.php?no=1029142</link><description><![CDATA[ROME & CAMBRIDGE, Mass.--(Business Wire/Korea Newswire)--Angelini Pharma , part of the privately owned Angelini Industries, and Quiver Bioscience  (“Quiver”), a discovery technology and therapeutics company advancing programs for the treatment of central nervous system (CNS) disorders, announced today that they have entered into a collaboration and licensing agreement to advance novel therapeutics for...]]></description><image><url><![CDATA[https://file.newswire.co.kr/data/datafile2/thumb/2026/02/31017998_20260224162159_2675547983.jpg]]></url></image><pubDate>Tue, 24 Feb 2026 16:26:38 +0900</pubDate></item></channel></rss>